Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2008
Business Overview: Novavax is a clinical-stage biotechnology company developing novel vaccines using proprietary virus-like-particle (VLP) technology. Key targets include H5N1 pandemic influenza, seasonal influenza, Varicella Zoster, and Respiratory Syncytial Virus (RSV). The company has transitioned away from its previous specialty pharmaceutical business (Estrasorb), which is now reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Total Revenues | $194 | $994 | - |
| Net Loss | $(7,842) | $(24,969) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.40) | - |
| Cash and Cash Equivalents | - | - | $36,794 |
| Short-term Investments | - | - | $8,450 |
| Total Current Assets | - | - | $46,681 |
| Total Current Liabilities | - | - | $30,185 |
| Convertible Notes (Current) | - | - | $21,676 |
| Accumulated Deficit | - | - | $(224,696) |
Note: Revenue is derived primarily from contract research and development ($142k for Q3; $925k for YTD) and royalties/milestones ($52k for Q3; $69k for YTD). There were no net product sales from continuing operations.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 76% in Q3 2008 compared to Q3 2007 ($194k vs. $814k), primarily due to the completion of government contracts and the discontinuation of Gynodiol sales.
- Operating Expenses: Research and Development (R&D) expenses increased 50% in Q3 2008 ($8.7M vs. $5.8M) due to expanded clinical trials for influenza vaccines. Conversely, General and Administrative (G&A) expenses decreased 59% ($1.3M vs. $3.1M), largely driven by a $1.2M accounting correction regarding notes receivable from former directors.
- Discontinued Operations: The company recorded a net income of $2.5M from discontinued operations in Q3 2008, compared to a loss of $1.2M in the prior year. This improvement resulted from revenue recognition related to the sale of Estrasorb assets to Graceway Pharmaceuticals.
- Liquidity Position: Cash and cash equivalents increased significantly to $36.8M from $4.4M at year-end 2007, bolstered by a $17.6M registered direct offering in July 2008 and proceeds from the Graceway transaction.
Guidance, Outlook, and Risks
- Clinical Progress: The company reported favorable Phase I/IIa results for its H5N1 pandemic vaccine in August 2008. Phase II trials for the seasonal influenza vaccine began in September 2008, with top-line data expected in Q4 2008. A dose-ranging study in the elderly has been delayed pending results from the healthy adult study.
- Liquidity Outlook: Management estimates current cash and investments are sufficient to fund operations through the third quarter of 2009. This projection assumes a 50% cash payoff of the $22.0M convertible notes due in July 2009 (requiring $11.0M cash), with the remainder potentially paid in stock. The company plans to raise additional capital in 2009.
- Convertible Notes: $22.0M in senior convertible notes mature on July 19, 2009. The company has the option to pay up to 50% in common stock. Failure to secure additional financing could force downsizing or delays in R&D.
- Market Risks: The company holds $8.45M in auction rate securities. While currently valued at cost, the company notes that failed auctions could lead to illiquidity and potential impairment charges if market conditions do not recover.
- Accounting Correction: The company corrected an error regarding notes receivable from former directors, reclassifying them as a reduction of equity rather than an asset. This resulted in a $1.2M credit to G&A expenses in Q3 2008.
Investor Verification Checklist
- Convertible Note Maturity: Verify the company's ability to refinance or convert the $22.0M notes due July 2009, specifically the cash requirement of $11.0M if the stock price does not trigger mandatory conversion.
- Auction Rate Securities: Monitor the liquidity status of the $8.45M investment in auction rate securities and any potential impairment charges in future filings.
- Clinical Trial Results: Await the release of top-line data for the seasonal influenza Phase II trial (expected Q4 2008) to assess the viability of the primary product pipeline.
- Cash Burn Rate: Track the rate of cash consumption against the $36.8M cash balance to confirm the runway through Q3 2009 remains valid.
- Related Party Notes: Review the status of the $1.57M in notes receivable from former directors, which are now netted against equity, to assess collection risks.